Teikoku Pharma USA Announces NMPA Approval of Lidoderm® in China on May 8, 2024

Teikoku Pharma USA (TPU) has announced that the National Medical Products Administration (NMPA) in China has approved Lidoderm® (a 5% lidocaine patch) for the treatment of Post Herpetic Neuralgia (PHN). This approval marks a significant milestone for TPU, which partnered with Link Healthcare Group (LHG) in 2018 under an exclusive licensing agreement to develop and distribute the product in China.

Lidoderm® is a topical treatment designed to address neuropathic pain associated with PHN, offering patients a non-systemic alternative. The recommended application schedule for the patch is 12 hours on and 12 hours off, with the possibility of applying up to three patches simultaneously. This method provides a controlled and targeted relief from pain.

In the United States, Lidoderm® is marketed by TPU Pharma, a subsidiary of Teikoku Pharma USA. Additionally, an authorized generic version of the 5% lidocaine patch is marketed by Endo USA, Inc. Internationally, the product is known as Versatis® and is distributed in Europe and Latin America by Grünenthal GmbH. Since its introduction, over 3.7 billion patches have been distributed globally, reflecting its widespread acceptance and efficacy.

Paul Mori, CEO of Teikoku Pharma USA, expressed satisfaction with the approval in China, highlighting the significance of entering this important market and the potential positive impact on patients suffering from PHN. Mori acknowledged the long journey to achieve this milestone but emphasized the importance of providing relief to those affected by this debilitating condition.

Teikoku Pharma USA has a strong presence in global markets through collaborations with various partners. The company specializes in both topical external preparations, such as hydrogels, tapes, and ointments, and systemic transdermal patches, underscoring its expertise in the pharmaceutical industry.

Lidoderm® is a hydrogel patch containing 5% lidocaine, specifically formulated to treat neuropathic pain associated with PHN. For detailed product and safety information, individuals are advised to consult the prescribing information available on the TPU Pharma website.

In summary, the approval of Lidoderm® by the NMPA in China represents a significant advancement for Teikoku Pharma USA and its mission to provide effective pain management solutions globally. This development promises to improve the quality of life for many patients suffering from Post Herpetic Neuralgia in China.